Next-generation sequencing has emerged as a powerful tool to illuminate "druggable" targets in oncology. Tumor heterogeneity and limitations in DNA quality and yield from formalin-fixed specimens, however, present formidable challenges to routine NGS analysis.
In this webinar, recorded Oct. 3, panelists Brian Dougherty and Gary Latham discuss the pre-analytical, analytical, and post-analytical hurdles for targeted NGS, and offer solutions using workflows that provide sensitive and accurate results for both discovery and downstream clinical applications.
The speakers also describe how these methods can accelerate drug development by enabling new insights into cancer biology that can inform targeted therapies and companion diagnostics and by guiding patient stratification and selection in clinical trials.
Results from a recent study
published in Genome Medicine
, "Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies," are also discussed.
Register to view the archived recording here